Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine liposomes
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral, Percutaneous
01
Overview
Bupivacaine liposome is an extended-release formulation of the amide-type local anesthetic bupivacaine, utilizing the DepoFoam multivesicular liposomal delivery technology. This system consists of numerous non-concentric lipid-based chambers that encapsulate the drug, allowing for a slow, controlled release of bupivacaine into the surrounding tissue over an extended period, typically providing analgesia for up to 72 hours. It is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for postsurgical regional analgesia. By blocking voltage-gated sodium channels on the neuronal membrane, it prevents the initiation and conduction of nerve impulses, thereby providing effective pain relief while potentially reducing the requirement for postoperative opioids.
- Brand names
- Exparel
- Other names
- liposomal bupivacainebupivacaine liposome injectable suspension
02
Targets
CaV (Voltage-gated calcium channel protein complex)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)ATP1A (Sodium/potassium-transporting ATPase)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bupivacaine liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine liposomes.